# Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study

> **NCT03886246** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 131 (actual)

## Conditions studied

- Generalized Pustular Psoriasis

## Interventions

- **DRUG:** Spesolimab
- **DRUG:** Spesolimab

## Key facts

- **NCT ID:** NCT03886246
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-29
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-04-27
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03886246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03886246, "Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03886246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*